Technical University of Munich

Helmholtz Zentrum Munchen Deutsches Forschungszentrum Fur Gesundheit Und Umwelt

Pls-Design Gmbh

Klinikum Der Technischen Universität München

Carsten Schmidt-Weber

Reinhard Bredehorst

Thomas Grunwald

Edzard Spillner

Kilian Eyerich

Constanze A Jakwerth

Bettina Knapp

Ulrich M Zissler

Markus Ollert

Adam M Chaker

The present invention relates to a method of diagnosing eczema and/or psoriasis, wherein said method differentiates between eczema and psoriasis, and comprises determining the expression of at least two markers in a sample taken from an individual, wherein said at least two markers are selected from CCL27, NOS2, IL36G, KLK13, SOST, NPTX1, PLA2G4D, GDA, IL36A, TGM1, CLEC4G, IL13, TCN1, TMPRSS11D and RHCG, provided that said at least two markers consist of or comprise (a) CCL27 and NOS2; (b) CCL27 and KLK13; (c) IL36G and KLK13; (d) CCL27 and IL36G; (e) NOS2 and IL36G; (f) NOS2 and KLK13; (g) SOST; or (h) NPTX1; and assessing on the basis of the expression of said at least two markers whether the individual is afflicted with eczema and/or psoriasis.

Differential diagnosis of eczema and psoriasis

The present invention relates to a ratio of immune cells for use in a method of predicting therapeutic success of an allergen-specific immunotherapy (AIT) in a patient suffering from or having a disposition to develop an allergic disease. Furthermore, the present invention also relates to a kit for predicting therapeutic success of an allergen-specific immunotherapy in a patient suffering from or having a disposition to develop an allergic disease. Furthermore, the present invention relates to a method of predicting therapeutic success of an allergen-specific immunotherapy (AIT) in a patient suffering from or having a disposition to develop an allergic disease.

Ratio of immune cells as prognostic indicator of therapeutic success in allergen-specific immunotherapy

The invention relates to a pharmaceutical composition for modulation of T cell and B cell responses by antigen- or allergen-specific immunotherapy in combination with peripheral tolerance-inducing phagocytosis, made of one or more preparations and comprising one or more matrices suitable for locally restricted sustained release of a physiologically effective dose of at least one antigen or allergen, liposomes tailored for effective phagocytosis, one or more immune modulators of phagocytosis, and one or more immune modulators suitable for enhancing the suppressive function of regulatory T cells at the site of antigen or allergen presentation.

Induction of antigen-specific tolerance by peripheral phagocytosis

The invention relates to a pharmaceutical composition made of one or more preparation and comprising a therapeutically effective dose of at least one recombinant human C3-derivative and at least one antigen f&#xfc;r vaccination.

Controlled activation of complement components for use as endogenous adjuvant

Growing community of inventors

Munich, Germany

Carsten Schmidt-Weber